Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Wakamoto: Profits Down due to Poor Stock Management
June 1, 2009
- Champix Cuts Lifetime Medical Spending by ¥30,000
June 1, 2009
- Average Operating Profit Rate Down to 0.38% for Top-Four Wholesalers
June 1, 2009
- Teijin: Pharma & HHC Business Remains Bullish
June 1, 2009
- JSMI Announces Vision for Activation of OTC Drug Industry
June 1, 2009
- Suzuken: Sharp Fall in Profits Despite 3.4% Increase in Sales
June 1, 2009
- Meiji HD: Generics Bolster Pharma Business
June 1, 2009
- Reform of Profit Structure "Task of Pressing Urgency": Mr Kumakura
June 1, 2009
- Kyowa Kirin: Nesp Injection Plastic Syringe
May 25, 2009
- Mediceo Paltac to Invite 1,000 Employees to Early Retirement
May 25, 2009
- IMS Health Revises Its Forecast for Global Drug Sales Downward
May 25, 2009
- Kyowa Kirin Licenses Anti-LIGHT Antibody to sanofi-aventis
May 25, 2009
- JCR (Japan College of Rheumatology) 2009
May 25, 2009
- Shionogi to Acquire Pain-Focused US Company
May 25, 2009
- CS Yakuhin to Acquire Part of OTC Drugs Wholesale Business from Tomita Health Care
May 25, 2009
- Takeda to Acquire IDM Pharma
May 25, 2009
- Eisai: Profits Show Sharp Rebound with 6.5% Increase in Sales
May 25, 2009
- Santen: Overseas Sales Affected by Strong Yen
May 25, 2009
- Korosho to Invite Public Comments on Proposed Transient Measure
May 25, 2009
- Shionogi: Sales Up 6.2%; Crestor Continues to Drive Business
May 25, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…